On May, 14 Dicerna Pharmaceuticals, Inc. (DRNA) Analysts See $-0.30 EPS

April 17, 2018 - By Theresa Judd

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
During Q4 2017 the big money sentiment increased to 3. That’s change of 2.21, from 2017Q3’s 0.79. 6 investors sold all, 5 reduced holdings as Dicerna Pharmaceuticals, Inc. ratio is positive. 15 increased positions while 18 funds took positions. Funds hold 29.10 million shares thus 180.62% more from 2017Q3’s 10.37 million shares.
Geode Cap Mgmt Ltd accumulated 0% or 91,737 shs. Fmr Ltd Liability Corporation accumulated 1.71 million shs. Manufacturers Life Insurance The holds 0% or 806 shs in its capital. Palo Alto Invsts Limited Liability Com reported 0.19% stake. Morgan Stanley reported 1,874 shs. Ra Cap Management Limited Liability invested in 4.97M shs or 3.75% of the stock. Adage Cap Prns Gru Ltd has 0.04% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1.98 million shs. Moreover, Goldman Sachs Grp has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Vanguard Gp, a Pennsylvania-based fund reported 589,573 shs. Bridger Limited Liability Corporation holds 0.54% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 905,998 shs. Alpine Glob Management Lc stated it has 11,473 shs or 0.02% of all its holdings. 19,579 were reported by State Bank Of Ny Mellon. Cormorant Asset Mngmt Ltd Llc has invested 3.46% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Dimensional Fund Advisors Limited Partnership accumulated 18,244 shs. Camber Cap Llc reported 1.00M shs or 0.44% of all its holdings.

Dicerna Pharmaceuticals, Inc. registered $1.98 million net activity with 1 insider purchase and 1 insider sale since December 18, 2017. Weissman James B had sold 1,035 shs worth $13,455 on Monday, March 19.

On May, 14. Investors expect Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to publish its quarterly earnings, Faxor reports. Analysts forecast $-0.30 earnings per share. That’s $0.38 up or 55.88 % from 2017’s earnings of $-0.68. Wall Street now sees -66.67 % EPS growth despite Dicerna Pharmaceuticals, Inc. last quarter’s EPS of $-0.90. Its shares touched $10.26 on during the last trading session after 0.48% change.Currently Dicerna Pharmaceuticals, Inc. is uptrending after 274.53% change in last April 17, 2017. DRNA has also 26,066 shares volume. DRNA outperformed the S&P 500 by 262.98%.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

Total analysts of 8 have positions in Dicerna Pharma (NASDAQ:DRNA) as follows: 4 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 50%. Since November 2, 2017 according to StockzIntelligence Inc Dicerna Pharma has 9 analyst reports. On Monday, February 5 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by SunTrust. On Friday, March 9 Stifel Nicolaus maintained the shares of DRNA in report with “Buy” rating. On Tuesday, March 27 the firm earned “Hold” rating by FBR Capital. On Friday, March 9 the rating was initiated by Chardan Capital Markets with “Hold”. On Wednesday, April 11 the rating was initiated by Cowen & Co with “Buy”. On Friday, March 23 the company was downgraded by H.C. Wainwright. The stock rating was maintained by Stifel Nicolaus with “Buy” on Thursday, November 2.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is worth $531.13 million. The company's preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Last it reported negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.